Google's secret weapon against cancer might be an AI algorithm

Isomorphic Labs, a drug discovery firm under Alphabet, is on the verge of a groundbreaking advancement in cancer treatment. After extensive development, the company is preparing to launch human clinical trials for cancer therapies created entirely through artificial intelligence. Emerging from Google DeepMind in 2021, Isomorphic Labs is leveraging the innovative AlphaFold system, which previously amazed scientists by accurately predicting protein structures—key elements in biological processes. This technology has evolved into AlphaFold 3, enhancing its ability to simulate protein interactions with DNA, RNA, and drug molecules. This capability enables researchers to model drug development processes without the need for initial lab experiments, potentially transforming a traditionally lengthy and expensive process into a more efficient and targeted approach. In a recent conversation with Fortune, Isomorphic Labs President Colin Murdoch revealed that the company is “very close” to initiating its clinical trials. He noted, “There are people sitting in our office in King’s Cross, London, working and collaborating with AI to design drugs for cancer. That’s happening right now.” The firm merges its AI prowess with conventional pharmaceutical insight and is collaborating with major pharmaceutical companies such as Novartis and Eli Lilly, both of which entered into long-term research partnerships with Isomorphic in 2024. In April, Isomorphic secured $600 million in a significant funding round led by Thrive Capital. This investment is being directed towards the development of in-house drug candidates, with oncology and immunology as initial focal points. Murdoch expressed ambition to create a “world-class drug design engine” that can enhance the success rate of drug development, which is often plagued by high failure rates and exorbitant research costs. “We’re trying to speed them up, reduce the cost, but also really improve the chance that we can be successful,” he stated. However, the integration of AI in healthcare, especially during such a crucial development phase, presents a multitude of challenges alongside its potential. While the prospect of expedited treatments is appealing, issues concerning transparency, accessibility, and accountability are emerging. The “black box” aspect of AI, where outcomes are produced without a clear understanding of the underlying processes, could pose significant hurdles in medicine, where trust and regulatory adherence are paramount. Moreover, critical questions arise: Who holds the rights to drugs created by AI? Will these treatments be affordable or relegated to exclusive patents? And, in the event of complications, who bears the responsibility: the developers, the AI system, or the corporation? As of now, Isomorphic Labs has not provided additional comments on these matters. This development signifies a pivotal moment not only for Alphabet but for the entire pharmaceutical sector. Should Isomorphic's trials prove successful, they could fundamentally alter the landscape of drug discovery and delivery. The future of this innovation will hinge not just on the capabilities of AI, but on the readiness of regulators, ethicists, and the public to embrace this new paradigm in medicine.